Accession Number : ADA267126


Title :   The Use of CD4/GP120 Interactions in the Development of Anti-HIV Drugs and Vaccines


Descriptive Note : Annual rept.,


Corporate Author : TEL-AVIV UNIV (ISRAEL) DEPT OF CELL RESEARCH AND IMMUNOLOGY


Personal Author(s) : Gershoni, Jonathan


Full Text : https://apps.dtic.mil/dtic/tr/fulltext/u2/a267126.pdf


Report Date : 30 Sep 1992


Pagination or Media Count : 20


Abstract : The HIV envelope protein, gpl2O binds to the CD4 cell surface protein and thereby the virus enters T4 helper lymphocytes. This process of virus entry might be associated with the presentation of unique epitopes of the gpl2O that become revealed only as a result of virus binding to its target cell. The purpose of this research has been to identify cryptic epitopes that become accessible due to induced conformational changes that result from that complex formation of gpl2O with CD4. Thus CD4/gpl2O complexes have been used to immunize mice and monoclonal antibodies have been generated. At least 7 ant;-bodies have been identified as having preferred affinity for the above complex. These antibodies are now being characterized. They represent 3 distinct epitopes as has been determined by competitive ELISA assays. moreover, using a syncytium assay they have been evaluated for their neutralizing activity.... AIDS, HIV, Epitopes, Biotechnology, Vaccines, Lab Animals, CD4, GP 120 Epitopes, Mice, RA I.


Descriptors :   *ANTIBODIES , *HUMAN IMMUNODEFICIENCY VIRUSES , *ACQUIRED IMMUNE DEFICIENCY SYNDROME , *VACCINES , STRATEGY , PROTEINS , MICE , LABORATORY ANIMALS , FORMICIDAE , BIOTECHNOLOGY , LYMPHOCYTES , VIRUS DISEASES , MONOCLONAL ANTIBODIES , TARGETS , SURFACES


Subject Categories : Medicine and Medical Research
      Microbiology


Distribution Statement : APPROVED FOR PUBLIC RELEASE